Completed
Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3
NCT02227823
- Conditions
- Central Nervous System Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +9 more
- Locations
-
- Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle Liège, Belgium